Efalizumab Is Safe For faraway-Term Use In Psoriasis Patients

May 28th, 2008 | Category: Dermatology

A review of details based on ten years of experience using efalizumab (Raptiva®) to treat chronic plaque psoriasis confirms that that the drug has a favorable long-term safety profile.

The chronic plaque anatomy of psoriasis accounts for about 75 percent of psoriasis cases.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Efalizumab (Raptiva) Is Safe For lengthy-Term Use In Psoriasis Patients
  • Psoriasis - 10 Year Clinical Experience Confirms Raptiva’s faraway-Term Safety Profile
  • Drug Effective In Treatment Of Heavy Psoriasis Patients
  • Education Needed For lengthy-Term Care Insurance
  • Long-Term Improvement Of Chronic Plaque Psoriasis Shown In Ustekinumab Phase 3 Data

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.